Merck, Inc.
🇵🇭Philippines
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT00202839
V260 Registration Study (V260-013)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT00166517
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 357
- Registration Number
- NCT00160251
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 134
- Registration Number
- NCT00157898
A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00157872
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 176
- Registration Number
- NCT00157950
Osteoporosis Disease Management Demonstration Project (0000-040)
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT00145067
Comparison of Osteoporosis Disease Management Strategies (0000-039)
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4685
- Registration Number
- NCT00145080
A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 274
- Registration Number
- NCT00140933
- Locations
- 🇫🇷
Laboratoires Merck Sharp & Dohme - Chibret, Paris Cedex 8, France
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 62
- Registration Number
- NCT00140894
© Copyright 2024. All Rights Reserved by MedPath